Moreover, the absence of clinically applicable biomarkers to guide treatment throughout the disease course, coupled with limited therapeutic options and a median survival of only 35 years post-diagnosis, underscores the urgent need for better diagnostic and therapeutic strategies (Table 1, although first-generation antifibrotic drugs, such as pirfenidone and nintedanibapproved over a decade agohave demonstrated efficacy in slowing IPF progression and improving survival rates in clinical trials, their benefits are constrained by significant side effects (e.g., nausea, diarrhea, and photosensitivity) that compromise long-term tolerability (Table 2) reduce the rate of lung function decline in clinical studies ( TABLE 1 Summary of FDA-approved drugs for idiopathic pulmonary fibrosis
For each study quality domain, the reviewers assigned a rating of good, adequate, deficient, not reported (an animal toxicological-specific rating that could carry the same functional interpretation as adequate or deficient), or critically deficient
Esse perigo [do uso indiscriminado] e o quo urgente falar sobre isso." Os peptdeos se transformaram em uma das palavras mais populares do mercado de esttica, longevidade e performance fsica nos ltimos anos
CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer
